FAIZA MAREDIA: Open Payments
NPI 1326788076 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 45 payments from 10 companies in 2025. Trend: 2023 $688 · 2024 $620 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $202 |
| GENZYME CORPORATION | 3 | $85 |
| Phathom Pharmaceuticals, Inc. | 6 | $72 |
| Celltrion USA Inc. | 4 | $64 |
| PFIZER INC. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Ardelyx, Inc. | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Braintree Laboratories, Inc. | 1 | $18 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, VOQUEZNA, VEGZELMA, SKYRIZI, VELSIPITY, VOWST.
Industry payments across TX — which companies pay providers there.
